MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 6: exploration of aromatic substituents.

Ken-ichi Yoshida,K. Nakayama,Y. Yokomizo,M. Ohtsuka,M. Takemura,K. Hoshino,H. Kanda,K. Namba,H. Nitanai,Jason Z. Zhang,V. Lee,W. Watkins

DOI: https://doi.org/10.1016/J.BMC.2006.08.037

IF: 3.461

2006-12-15

Bioorganic & Medicinal Chemistry

Abstract:

What problem does this paper attempt to address?

Targeted Drug Delivery Systems for Curcumin in Breast Cancer Therapy

Mian Huang,Bing-Tao Zhai,Yu Fan,Jing Sun,Ya-Jun Shi,Xiao-Fei Zhang,Jun-Bo Zou,Jia-Wen Wang,Dong-Yan Guo

DOI: https://doi.org/10.2147/IJN.S410688

2023-07-28

Abstract:Breast cancer (BC) is the most prevalent type of cancer in the world and the main reason women die from cancer. Due to the significant side effects of conventional treatments such as chemotherapy and radiotherapy, the search for supplemental and alternative natural drugs with lower toxicity and side effects is of interest to researchers. Curcumin (CUR) is a natural polyphenol extracted from turmeric. Numerous studies have demonstrated that CUR is an effective anticancer drug that works by modifying different intracellular signaling pathways. CUR's therapeutic utility is severely constrained by its short half-life in vivo, low water solubility, poor stability, quick metabolism, low oral bioavailability, and potential for gastrointestinal discomfort with high oral doses. One of the most practical solutions to the aforementioned issues is the development of targeted drug delivery systems (TDDSs) based on nanomaterials. To improve drug targeting and efficacy and to serve as a reference for the development and use of CUR TDDSs in the clinical setting, this review describes the physicochemical properties and bioavailability of CUR and its mechanism of action on BC, with emphasis on recent studies on TDDSs for BC in combination with CUR, including passive TDDSs, active TDDSs and physicochemical TDDSs.
[Etiology and management of venous pain during intravenous administration of oxaliplatin].

K. Matsuyama,H. Mishima,H. Ueno,Kinuyo Kajihara,Akiko Morioka,S. Morimoto,K. Yamauchi,Y. Honda,K. Komori,T. Tsujinaka

2011-03-01

Abstract:In Japan, XELOX (capecitabine plus oxaliplatin) was approved for the treatment of advanced/recurrent colorectal cancer in September 2009. However, patients treated with XELOX sometimes experience intense, sporadic venous pain during administration of oxaliplatin through peripheral vein. To investigate the etiology and management of this event, we measured the titratable acidity, osmotic pressure, and pH of 5% dextrose in water (D5W) containing oxaliplatin with or without dexamethasone. The dexamethasone-containing solution was then tested for its efficacy in venous pain relief. D5W containing oxaliplatin had a pH of approximately 4. 8, whereas the titratable acidity and osmotic pressure were 0. 1 mEq/L and 300-320 mOsm/L, respectively, suggesting that the venous pain was partly attributable to the pH.When 1. 65-6. 6 mg of dexamethasone was added to this solution, the pH of the resulting solution was increased to 6. 5-7. 6. Moreover, pain was relieved in patients administered oxaliplatin with dexamethasone in D5W. When adjusted for pH by the addition of 1. 65-3. 3 mg of dexamethasone, oxaliplatin in D5W is associated with less venous pain without decreasing oxaliplatin content although it is not generally recommended to dissolve oxaliplatin in a basic solution since it is unstable under alkaline conditions.
Highly Soluble and Stable, High Release Rate Nanocellulose Codrug Delivery System of Curcumin and AuNPs for Dual Chemo-Photothermal Therapy

Yan Tian,Dongmei Jia,Mahmut Dirican,Meng Cui,Dongjun Fang,Chaoyi Yan,Jingyi Xie,Yi Liu,Chunxing Li,Junjun Fu,Hao Liu,Gang Chen,Xiangwu Zhang,Jinsong Tao

DOI: https://doi.org/10.1021/acs.biomac.1c01367

2022-01-01

Biomacromolecules

Abstract:As a natural antitumor drug, curcumin (CUR) has received increasing attention from researchers and patients due to its various medicinal properties. However, currently CUR is still restricted due to its low and stand-alone therapeutic effects that seriously limit its clinical application. Here, by using cellulose nanocrystals (CNCs) as a nanocarrier to load CUR and AuNPs simultaneously, we developed a hybrid nanoparticle as a codrug delivery system to enhance the low and stand-alone therapeutic effects of CUR. Aided with the encapsulation of beta-cydodextrin (mu CD), both the solubility and the stability of CUR are greatly enhanced (solubility increased from 0.89 to 131.7 mu g/mL). Owing to the unique rod-like morphology of CNCs, the system exhibits an outstanding loading capacity of 31.4 mu g/mg. Under the heat effects of coloaded AuNPs, the system demonstrates a high release rate of 77.63%. Finally, with CNC as a bridge nanocarrier, all aforementioned functions were integrated into one hybrid nanoparticle. The all-in-one integration ensures CUR to have enhanced therapeutic effects and enables the delivery system to exhibit combined chemo-photothermal therapy outcomes. This work presents a significant step toward CUR's clinical application and provides a new strategy for effective and integrative treatment of tumor disease.
Curcumin and its nano-formulations: Defining triple-negative breast cancer targets through network pharmacology, molecular docking, and experimental verification

Zhicheng Deng,Guanghui Chen,Yonghui Shi,Ying Lin,Jiebin Ou,Hua Zhu,Junyan Wu,Guocheng Li,Li Lv

DOI: https://doi.org/10.3389/fphar.2022.920514

IF: 5.6

2022-08-09

Frontiers in Pharmacology

Abstract:Background: Curcumin (CUR) displays the capability of suppressing the proliferation and metastasis of various cancer cells. However, the effects and underline mechanisms of CUR to treat triple-negative breast cancer (TNBC) have not been systematically elucidated with an appropriate method. Methods: In the present research, a combination method of network pharmacology, molecular docking, and in vitro bio-experiment was used to investigate the pharmacological actions and underline mechanisms of CUR against TNBC. First, common targets of CUR and TNBC were screened via Venny 2.1.0 after potential CUR-related targets and targets of TNBC were got from several public databases. Then, the Gene Ontology (GO) function and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment were performed on the Metascape website, and the network of compound-targets-pathways was constructed via Cytoscape software. Moreover, the network of protein-protein interaction was constructed by the STRING database to screen potential targets. Moreover, molecular docking was applied to affirm the interaction of CUR with the screened top 10 potential targets. Finally, in vitro experiments were used to further verify the effects and mechanisms of CUR and its nano-formulation (CUR-NPs) against TNBC. Results: Forty potential targets of CUR against TNBC were obtained. STAT3, AKT1, TNF, PTGS2, MMP9, EGFR, PPARG, NFE2L2, EP300, and GSK3B were identified as the top 10 targets of CUR against TNBC. In vitro experiment verified that CUR and CUR-NPs could not only restrain the invasion, migration, and proliferation of MDA-MB-231 cells but also induce their apoptosis. In addition, molecular docking demonstrated that CUR could bind spontaneously with the screened top 10 targeted proteins, and a real-time PCR experiment demonstrated that both CUR and CUR-NPs could downregulate the genetic expression levels of the 10 targets. Moreover, according to the CUR-targets-pathways network, PI3K-Akt, EGFR tyrosine kinase inhibitor resistance, JAK-STAT, Foxo, and HIF-1 signaling pathways were identified as the important pathways of CUR effects on TNBC. Among them, the inhibiting effects of CUR and CUR-NPs on the JAK-STAT signaling pathway were further verified by the western blot analysis. Conclusion: Taken together, the present research demonstrates that CUR and CUR-NPs have pharmacological effects against TNBC via a multi-target and multi-pathway manner.

pharmacology & pharmacy
Nanoscale Formulations: Incorporating Curcumin into Combination Strategies for the Treatment of Lung Cancer

Quhui Wu,Huiping Ou,Yan Shang,Xi Zhang,Junyong Wu,Fuyuan Fan

DOI: https://doi.org/10.2147/DDDT.S311107

2021-06-21

Abstract:Lung cancer remains the most common cancer worldwide. Although significant advances in screening have been made and early diagnosis strategies and therapeutic regimens have been developed, the overall survival rate remains bleak. Curcumin is extracted from the rhizomes of turmeric and exhibits a wide range of biological activities. In lung cancer, evidence has shown that curcumin can markedly inhibit tumor growth, invasion and metastasis, overcome resistance to therapy, and even eliminate cancer stem cells (CSCs). Herein, the underlying molecular mechanisms of curcumin were summarized by distinct biological processes. To solve the limiting factors that curtail the clinical applications of curcumin, nanoformulations encapsulating curcumin were surveyed in detail. Nanoparticles, including liposomes, micelles, carbon nanotubes (CNTs), solid lipid nanoparticles (SLNs), nanosuspensions, and nanoemulsions, were explored as proper carriers of curcumin. Moreover, it was firmly verified that curcumin has the ability to sensitize lung cancer cells to chemotherapeutic drugs, such as cisplatin and docetaxel, and to various targeted therapies. Regarding the advantages and drawbacks of curcumin, we concluded that combination therapy based on nanoparticles would be the optimal approach to broaden the application of curcumin in the clinic in the near future.
Real-time--directed M-mode echocardiography: a new technique for accurate and rapid quantitation of the fetal preejection period and ventricular ejection time of the right and left ventricles.

G. Devore,R. Donnerstein,C. Kleinman,J. Hobbins

DOI: https://doi.org/10.1016/0002-9378(81)90617-7

IF: 9.8

1981-10-15

American Journal of Obstetrics and Gynecology

Abstract:
Therapeutic Nanoparticles Based on Curcumin and Bamboo Charcoal Nanoparticles for Chemo-Photothermal Synergistic Treatment of Cancer and Radioprotection of Normal Cells

Jiani Xie,Yuan Yong,Xinghua Dong,Jiangfeng Du,Zhao Guo,Linji Gong,Shuang Zhu,Gan Tian,Shicang Yu,Zhanjun Gu,Yuliang Zhao

DOI: https://doi.org/10.1021/acsami.7b02622

IF: 9.5

2017-01-01

ACS Applied Materials & Interfaces

Abstract:Low water solubility, extensive metabolism, and drug resistance are the existing unavoidable disadvantages of the insoluble drug curcumin in biomedical applications. Herein, we employed d-α-tocopherol polyethylene glycol 1000 succinate (TPGS)-functionalized near-infrared (NIR)-triggered photothermal mesoporous nanocarriers with bamboo charcoal nanoparticles (TPGS-BCNPs) to load and deliver curcumin for improving its bioavailability. This system could considerably increase the accumulation of curcumin in cancer cells for enhanced curcumin bioavailability via simultaneously promoting the cellular internalization of the as-synthesized composite (TPGS-BCNPs@curcumin) by the size effect of NPs and considerably triggering controlled curcumin release from TPGS-BCNPs@curcumin by NIR stimulation and reducing efflux of curcumin by the P-glycoprotein (P-gp) inhibition of TPGS, so as to enhance the therapeutic effect of curcumin and realize a better chemo-photothermal synergetic therapy in vitro and in vivo. Besides cancer therapy, studies indicated that curcumin and some carbon materials could be used as radical scavengers that play an important role in the radioprotection of normal cells. Hence, we also investigated the free-radical-scavenging ability of the TPGS-BCNPs@curcumin composite in vitro to preliminarily evaluate its radioprotection ability for healthy tissues. Therefore, our work provides a multifunctional delivery system for curcumin bioavailability enhancement, chemo-photothermal synergetic therapy of cancer, and radioprotection of healthy tissues.
Curcumin Administration Routes in Breast Cancer Treatment

Bianca Mayo,Silvana Penroz,Keila Torres,Layla Simón

DOI: https://doi.org/10.3390/ijms252111492

IF: 5.6

2024-10-27

International Journal of Molecular Sciences

Abstract:Breast cancer is a public health concern worldwide, characterized by increasing incidence and mortality rates, requiring novel and effective therapeutic strategies. Curcumin is a bioactive compound extracted from turmeric with several pharmacological activities. Curcumin is a multifaceted anticancer agent through mechanisms including the modulation of signaling pathways, inhibition of cell proliferation, induction of apoptosis, and production of reactive oxygen species. However, the poor water solubility and bioavailability of curcumin create important barriers in its clinical application. This review elaborates on the therapeutic potential of curcumin in breast cancer treatment, focusing on the efficacy of different administration routes and synergistic effects with other therapeutic agents. The intravenous administration of curcumin-loaded nanoparticles significantly improves bioavailability and therapeutic outcomes compared to oral routes. Innovative formulations, such as nano-emulsifying drug delivery systems, have shown promise in enhancing oral bioavailability. While intravenous delivery ensures higher bioavailability and direct action on tumor cells, it is more invasive and expensive than oral administration. Advancing research on curcumin in breast cancer treatment is essential for improving therapeutic outcomes and enhancing the quality of life of patients.

biochemistry & molecular biology,chemistry, multidisciplinary
Nanocurcumin in cancer treatment: a comprehensive systematic review

Meshkat Boroughani,Amir Kian Moaveni,Parsa Hatami,Neda Mansoob Abasi,Seyedeh Asrin Seyedoshohadaei,Arash Pooladi,Yousef Moradi,Ramyar Rahimi Darehbagh

DOI: https://doi.org/10.1007/s12672-024-01272-x

2024-10-01

Abstract:Background: Curcumin, a compound in turmeric, shows potential in cancer treatment but is hindered by low bioavailability and solubility. Nanocurcumin, enhanced through nanotechnology, addresses these limitations, offering potential in oncological applications. This review systematically examines the efficacy, bioavailability, and safety of nanocurcumin in cancer treatment, collating data from in vitro, in vivo, and clinical studies. Methods: A comprehensive systematic search was conducted across four major databases: PubMed (Medline), Scopus, Web of Science, and Embase (up to February 2024). The selection criteria were based on the PICOT structure, and studies were assessed for risk of bias using the Cochrane bias risk tool for clinical studies and related checklists for in vitro and in vivo studies. Statistical analyses were performed in STATA software version 17. Results: In total, 8403 articles were identified and assessed, and then only 61 articles were found eligible to be included. Nanocurcumin formulations, especially with Poly (lactic-co-glycolic acid) (PLGA), displayed superior solubility and therapeutic efficacy. In vitro studies highlighted its enhanced cellular uptake and anti-proliferative effects, particularly against cervical cancer cells. In vivo studies confirmed its chemopreventive efficacy and potential synergy with other cancer therapies. Though in early stages, clinical trials showed promise in reducing side effects and improving efficacy in cancer treatments. Conclusion: Nanocurcumin shows promise as an innovative approach in cancer therapy, potentially offering improved efficacy and reduced side effects compared to traditional treatments. Early clinical trials indicate its potential to enhance the quality of life for cancer patients by mitigating treatment-related toxicities and improving therapeutic outcomes. However, larger randomized controlled trials are necessary to definitively establish its clinical efficacy, optimal dosing regimens, and long-term safety profile across various cancer types. As research progresses, nanocurcumin could become a valuable addition to the oncologist's toolkit, particularly in combination therapies or for patients intolerant to conventional treatments. Future clinical studies should focus on optimizing treatment protocols, identifying responsive patient populations, and assessing long-term outcomes to facilitate the translation of these promising findings into standard clinical practice.
Curcumin, its derivatives, and their nanoformulations: Revolutionizing cancer treatment

Iftikhar Ahmad,Sameer Ahmad,Ausaf Ahmad,Torki A. Zughaibi,Mahmoud Alhosin,Shams Tabrez

DOI: https://doi.org/10.1002/cbf.3911

2024-01-02

Cell Biochemistry and Function

Abstract:Curcumin is a natural compound derived from turmeric and can target malignant tumor molecules involved in cancer propagation. It has potent antioxidant activity, but its effectiveness is limited due to poor absorption and rapid elimination from the body. Various curcumin derivatives have also shown anticancer potential in in‐vitro and in‐vivo models. Curcumin can target multiple signaling pathways involved in cancer development/progression or induce cancer cell death through apoptosis. In addition, curcumin and its derivatives could also enhance the effectiveness of conventional chemotherapy, radiation therapy and reduce their associated side effects. Lately, nanoparticle‐based delivery systems are being developed/explored to overcome the challenges associated with curcumin's delivery, increasing its overall efficacy. The use of an imaging system to track these formulations could also give beneficial information about the bioavailability and distribution of the nano‐curcumin complex. In conclusion, curcumin holds significant promise in the fight against cancer, especially in its nanoform, and could provide precise delivery to cancer cells without affecting normal healthy cells.

cell biology,biochemistry & molecular biology
Curcumin Delivery Systems: How Far from Clinical Application in Tumor Therapy?

Yuanru Wang,Lubiao Liang,Yajin Zhao

DOI: https://doi.org/10.1177/1934578x231222102

IF: 1.496

2024-02-01

Natural Product Communications

Abstract:Curcumin, a natural polyphenol compound found in turmeric, exhibits significant anti-cancer activity in preclinical studies. However, its clinical application is limited by poor bioavailability and low solubility in aqueous media. To overcome these challenges, various curcumin delivery systems (CDSs) have been developed to enhance the pharmacokinetics and pharmacodynamics of curcumin, aiming to improve its solubility, stability, and targeted delivery to tumor cells. Preclinical studies have shown that CDSs can improve pharmacokinetics, enhance anti-tumor efficacy, and reduce toxicity in various cancers. Several CDSs have also advanced into clinical trials, demonstrating safety and efficacy in cancer patients. Despite the promising results, challenges remain, such as optimizing formulation and dosage, investigating curcumin's influence on the carriers in drug delivery and release, evaluating long-term safety and toxicity, and conducting large-scale clinical trials. Understanding the effect of gut microbiota on CDSs metabolism and bioavailability is critical for enhancing their clinical effectiveness in tumor therapy. Further research and development are necessary to fully exploit the potential of CDSs in cancer treatment. This review summarizes recent progress in CDSs research and their potential application in tumor therapy, encompassing formulation strategies, delivery routes, as well as preclinical and clinical evaluations. It not only provides valuable insights into the future rational design and development of curcumin dosage forms and their cancer therapeutic potential but also facilitates the clinical translation of curcumin and CDSs.

chemistry, medicinal,food science & technology
Chapter 14, Materials modelling and characterisation for thermo-mechanics

Yangjian Xu,L. Liang

DOI: https://doi.org/10.1109/esime.2005.1502839

Abstract:Mechanical Properties of Sintered Kovar Alloy for Structure Components of OpticalDevices . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Liao K. C., Feng H.P., Cheng C. D., Tsai H.H., Shieh W B. Fracture and Delamination of Thin Multilayers on Ultra-thin Silicon . . . . . . . . . . . . . . . . G. Kravchenko, J. Bagdahn Models correlation and comparison for solder joint reliability ..................... Yangjian Xu, Lihua Liang, Yong Liu Comparison of Lifetime Predictions with 3-D Finite Element Model of Power Electronics Devices . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S. Moreau, R. LRroy, :I: kqueu, R. Jirisian A reliability evaluation of lead-free ball grid array (BGA) solder joints through mechanical fatigue testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C. Ryan, J. Punch, 3. Rodgers FE analysis and experimental testing of a 4-pin ceramic test vehicle with tin-lead and tin-silver-copper solder joints . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . M. Spraul, W. Niichter; B. Wunderle, B. Michd Measurement of acce1er;ation factor for lead-free solder (SnAg3.8CuO.7) in thermal cycling test of BGA components and calibration of lead-free solder joint model for life prediction by finite e:lement analyses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . K. Anderssan, A. Perttula, U. Salmela, J. Sarkkii, M. Tammenma Complete Model for Interfacial stresses of a WO Layered Structure . . . . . . . . . . . . . . . . . D. Sujan, M. I! K Murthy, K. N. Seetharamu, A. Y. Hassan Viscoelastic characterization of fast curing moulding compounds ................... B.V Milosheva, K.M.B. Jansen, J.H.J. Janssen, H.J.L. Bressers, L.J. Ernst Experimental Investigation of the Adhesion Dilation with Negative Thermal Expansion LiAISi206 Fillers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . H-H. Tsai, C.D. Cheng, WB. Shieh, K.Z Lee, H.P. Feng Characterization of Non-Conductive Adhesives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D. Farley, A. Dasgupi'a, J.F. J. Caers, w1 E. Hua Modelling and Experiments on an Isothermal Fatigue Test for Solder Joints .......... S. Ridout, M. Dusek, 'C. Bailey, C, Hunt Modelling Methodology for Linear Elastic Compound Modelling Versus Visco-Elastic Compounld Modelling . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . R. B.R van Silfiout, J. G. J Beijer, G.Q. Zhang, W.D. van Driel 416
Enhanced breast cancer therapy using multifunctional lipid-coated nanoparticles combining curcumin chemotherapy and nitric oxide gas delivery

Zhirong Yan,Peihan Xiao,Peng Ji,Rongjian Su,Zhenkun Ren,Li Xu,Xun Qiu,Dan Li

DOI: https://doi.org/10.1038/s41598-024-69229-2

2024-08-05

Abstract:The limitations associated with conventional cancer treatment modalities, particularly for breast cancer, underscore the imperative for developing safer and more productive drug delivery systems. A promising strategy that has emerged is the combination of chemotherapy with gas therapy. We synthesized curcumin-loaded amorphous calcium carbonate nanoparticles (Cur-CaCO3) via a gas diffusion reaction in the present study. Subsequently, a "one-step" ethanol injection method was employed to fabricate lipid-coated calcium carbonate nanoparticles (Cur-CaCO3@LA-Lip) loaded with L-arginine, aimed at harnessing the synergistic effects of chemotherapy and nitric oxide to enhance antitumor efficacy. Transmission electron microscopy analysis revealed that Cur-CaCO3@LA-Lip nanoparticles were subspherical with a distinct lipid layer encapsulating the periphery. Fourier transform infrared spectroscopy, X-ray powder diffraction, and differential scanning calorimetry results confirmed the successful synthesis of Cur-CaCO3@LA-Lip. The nanoparticles exhibited significant drug loading capacities of 8.89% for curcumin and 3.1% for L-arginine. In vitro and in vivo assessments demonstrated that Cur-CaCO3@LA-Lip nanoparticles facilitated sustained release of curcumin and exhibited high cellular uptake, substantial tumor accumulation, and excellent biocompatibility. Additionally, the nanoparticles showed robust cytotoxicity and potent antitumor efficacy, suggesting their potential as a formidable candidate for breast cancer therapy.
A Novel Folic Acid Receptor-Targeted Drug Delivery System Based on Curcumin-Loaded β-Cyclodextrin Nanoparticles for Cancer Treatment

DOI: https://doi.org/10.2147/DDDT.S320119

2021-06-30

Abstract:Weiyong Hong, 1, 2, &ast Fangyuan Guo, 2, &ast Nan Yu, 2 Sanjun Ying, 2 Bang Lou, 2 Jiangqing Wu, 2 Ying Gao, 2 Xugang Ji, 2 Haiying Wang, 1 Aiqin Li, 3 Guoping Wang, 4 Gensheng Yang 2 1 Department of Pharmacy, Taizhou Municipal Hospital, Taizhou, 318000, People's Republic of China; 2 College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, 310014, People's Republic of China; 3 Zhejiang Share Bio-Pharm Co., Ltd, Hangzhou, 310019, People's Republic of China; 4 Zhejiang Dayang Biotech Group Co., Ltd, Hangzhou, 311616, People's Republic of China &astThese authors contributed equally to this work Correspondence: Gensheng Yang College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, 310014, People's Republic of China Tel +86571-88871077 Fax +86571-88320913 Email Purpose: A novel folate receptor-targeted β-cyclodextrin (β-CD) drug delivery vehicle was constructed to improve the bioavailability, biosafety, and drug loading capacity of curcumin. Controlled release and targeted delivery was achieved by modifying the nanoparticles with folic acid (FA). Methods: Folate-conjugated β-CD-polycaprolactone block copolymers were synthesized and characterized. Curcumin-loaded nanoparticles (FA-Cur-NPs) were structured by self-assembly. The physicochemical properties, stability, release behavior and tumor-targeting ability of the fabricated nanoparticles were studied. Results: The average particle size and drug loading of FA-Cur-NPs was 151.8 nm and 20.27%, respectively. Moreover, the FA-Cur-NPs exhibited good stability in vitro for 72 h. The drug release profiles showed that curcumin from FA-Cur-NPs was released significantly faster in a pH 6.4 phosphate buffered solution (PBS) than in pH 7.4, indicating that curcumin can be enriched around the tumor site compared with normal cells. Additionally, the internalization of FA-Cur-NPs was aided by FA receptor-mediated endocytosis, and its cytotoxicity was proportional to the cellular uptake efficiency. Furthermore, in vivo studies confirmed that FA-Cur-NPs exhibited marked accumulation in the tumor site and excellent antitumor activity. Conclusion: These findings suggest that FA-Cur-NPs are a promising approach for improving cancer therapy through active targeting and controllable release. Keywords: curcumin, β-CD-polycaprolactone copolymers, folate receptor, targeted drug delivery, HeLa cells Cancer is the most fatal disease threatening human health. According to GLOBOCAN estimates, there were approximately 19.3 million new cases and almost 10.0 million deaths in 2020. 1 Current therapeutic approaches developed for cancer treatment include chemotherapy, immunotherapy, radiation therapy, and surgical excision; 2–4 among them, chemotherapy is the most effective and inexpensive treatment. 5 However, poor targeting selectivity is the main drawback of traditional drugs, which usually cannot distinguish tumors from normal tissues. 6 Therefore, a high dose is administered, resulting in serious adverse effects (eg, side effects and multidrug resistance). 7 Curcumin exhibits a wide range of pharmacological activities such as anti-inflammation, antioxidant, antimicrobial, and anticancer. 8–10 Moreover, the anticancer activity with a high safe dose 11 and ability of multiple cell signaling pathways to regulate different tumors, such as breast, cervical, stomach, liver, and pancreatic cancers as well as colon and epithelial cell carcinomas have received the most attention. 12–15 However, the low water solubility, rapid decomposition, and lack of specific targeting of curcumin under physiological conditions limited its clinical application. 16 To overcome these barriers, nanotechnology has been applied for drug delivery, 17 and active targeted delivery through tumor microenvironment-stimuli responsive systems, such as pH-responsive, 18 , 19 redox-sensitive, 20 and targeting molecule-conjugated nanocarriers, 21 has been employed for tumor diagnosis and treatment. Targeting molecule-conjugated nanocarriers have been widely invest -Abstract Truncated-
Nano to rescue: repository of nanocarriers for targeted drug delivery to curb breast cancer

Poonam Banthia,Lokesh Gambhir,Asha Sharma,Dhiraj Daga,Neha Kapoor,Rishabh Chaudhary,Gaurav Sharma

DOI: https://doi.org/10.1007/s13205-022-03121-6

IF: 2.893

2022-02-13

3 Biotech

Abstract:Breast cancer is a heterogeneous disease with different intrinsic subtypes. The conventional treatment of surgical resection, chemotherapy, immunotherapy and radiotherapy has not shown significant improvement in the survival rate of breast cancer patients. The therapeutics used cause bystander toxicities deteriorating healthy tissues. The breakthroughs of nanotechnology have been a promising feat in selective targeting of tumor site thus increasing the therapeutic gain. By the application of nanoenabled carriers, nanomedicines ensure targeted delivery, stability, enhanced cellular uptake, biocompatibility and higher apoptotic efficacy. The present review focuses on breakthrough of nanoscale intervention in targeted drug delivery as novel class of therapeutics. Nanoenabled carriers like polymeric and metallic nanoparticles, dendrimers, quantum dots, liposomes, solid lipid nanoparticles, carbon nanotubes, drug-antibody conjugates and exosomes revolutionized the targeted therapeutic delivery approach. These nanoassemblies have shown additional effect of improving the solubility of drugs such as paclitaxel, reducing the dose and toxicity. The present review provides an insight on the different drug conjugates employed/investigated to curb breast cancer using nanocarrier mediated targeted drug delivery. However, identification of appropriate biomarkers to target, clearer insight of the biological processes, batch uniformity, reproducibility, nanomaterial toxicity and stabilities are the hurdles faced by nanodrugs. The potential of nano-therapeutics delivery necessitates the agglomerated efforts of research community to bridge the route of nanodrugs for scale-up, commercialization and clinical applications.

biotechnology & applied microbiology
[Immunomapping in localized bullous pemphigoid].

M. D. de Jong,S. Kardaun,R. Tupker,H. Seijen

1989-04-01

Abstract:A 70-year-old Caucasian patient is described, who presented with a bullous dermatosis on an amputation stump. The bullous lesions had developed after practice with a Kondylen-Bettung-Münster (KBM) prosthesis. The lesions disappeared completely after prednisone therapy and replacement of the prosthesis with a Thomas splint. The patient has remained free of symptoms ever since, even though prednisone was completely withdrawn after 9 months. According to skin immunofluorescence criteria, the patient suffered from pemphigoid, rather than epidermolysis bullosa acquisita as strongly suggested by the anamnesis. In particular, the presence of linear IgG at the level of the lamina lucida of the epidermal basement membrane zone and the localization of laminin antigen at the blister floor are highly suggestive of pemphigoid.
Platinum nanoparticles-embedded single-walled carbon nanotubes as a new carrier for curcumin delivery and investigating its anticancer effect on cell line 4T1

Ali Mohammadi,Fariba Bagheri,Yasamin Abutalebi,Afsoon Aghaei,Hossein Danafar

DOI: https://doi.org/10.1016/j.heliyon.2024.e33703

IF: 3.776

2024-06-26

Heliyon

Abstract:Cancer, a prevalent disease across various societies, presents a significant challenge in treatment research. Studies show that combination therapies are one of the methods that can help in the effective treatment of cancer. Chemotherapy and radiation therapy are among the main cancer treatments and in this project, for combined chemoradiotherapy treatment, carbon nanotubes were used as improved carriers of chemotherapy in tumors, as well as a substrate for the preparation of radiation sensitizers for local radiation therapy. Following the synthesis of CNT-Platinum-Curcumin nanoparticles (CNT-Pt-CUR), a series of analyses were conducted to verify the successful production of these nanoparticles. Techniques such as Transmission Electron Microscopy (TEM), Dynamic Light Scattering (DLS), UV-Vis spectroscopy, Fourier Transform Infrared Spectroscopy (FTIR), and X-Ray Diffraction (XRD) were employed. The characterization data revealed a spherical shape Pt nanoparticle morphology with an 8.5 nm diameter on rod-shape CNT, as observed through TEM. Furthermore, FTIR analysis confirmed the successful loaded of the drug into the nanoparticles, highlighting the potential of this approach in cancer treatment. Then, hemolysis and (3(-4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) tests on normal cells were used to assess the biocompatibility of CNT-Pt-CUR nanoparticles. It also explored the anticancer efficacy of these nanoparticles at varying concentrations against cancer cells, both with and without exposure to X-rays. The research confirmed the successful synthesis of these nanoparticles and demonstrated their potential impact on cell viability. Specifically, breast cancer cells exhibited heightened susceptibility to toxicity when exposed to nanoparticles and X-rays. Further analysis revealed that the toxicity of nanoparticles is dose-dependent, and modifying the surface of carbon nanotube (CNT) nanoparticles with CUR significantly reduced blood toxicity. Interestingly, nanoparticle toxicity was significantly amplified in the presence of X-rays, suggesting mechanisms such as DNA damage and increased reactive oxygen species (ROS) levels within cells.
Development of curcumin-loaded galactosylated chitosan-coated nanoparticles for targeted delivery of hepatocellular carcinoma

Mian Huang,Ji Liu,Yu Fan,Jing Sun,Jiang-Xue Cheng,Xiao-Fei Zhang,Bing-Tao Zhai,Dong-Yan Guo

DOI: https://doi.org/10.1016/j.ijbiomac.2023.127219

IF: 8.2

2023-10-18

International Journal of Biological Macromolecules

Abstract:Curcumin (CUR) has good antitumor effects, but its poor aqueous solubility severely limits its clinical application and the systemic nonspecific distribution of the free drug in tumor patients is a key therapeutic challenge. In order to overcome the limitations of free drugs and improve the therapeutic efficacy, we developed novel galactosylated chitosan (GC)-modified nanoparticles (GC@NPs) based on poly (ethylene glycol) methyl ether- block -poly (lactide- co -glycolide) (PEG-PLGA), which can target asialoglycoprotein receptor (ASGPR) expressed on hepatocellular carcinoma cells and have excellent biocompatibility. The results showed that the drug loading (DL) of CUR was approximately 4.56 %. A favorable biosafety profile was maintained up to concentrations of 500 μg/mL. Furthermore, in vitro cellular assays showed that GC@NPs could be efficiently internalized by HepG2 cells via ASGPR-mediated endocytosis and successfully released CUR for chemotherapy. More importantly, in vivo anti-tumor experiments revealed that GC@NPs were able to accumulate effectively within tumor sites through EPR effect and ASGPR-mediated endocytosis, leading to superior inhibition of tumor growth compared to free CUR. Overall, GC@NPs are a promising CUR nanocarrier for enhanced tumor therapy with a good biosafety profile.

polymer science,biochemistry & molecular biology,chemistry, applied
In Vivo Efficacy and Toxicity of Curcumin Nanoparticles in Breast Cancer Treatment: A Systematic Review

Alicia S. Ombredane,Vitória R. P. Silva,Laise R. Andrade,Willie O. Pinheiro,Mayara Simonelly,Jaqueline V. Oliveira,Andréia C. Pinheiro,Gabriel F. Gonçalves,Gisela J. Felice,Mônica P. Garcia,Patrícia M. Campos,Glécia V. S. Luz,Graziella A. Joanitti

DOI: https://doi.org/10.3389/fonc.2021.612903

IF: 4.7

2021-03-09

Frontiers in Oncology

Abstract:Breast cancer is one of the most prevalent types of malignant tumors in the world, resulting in a high incidence of death. The development of new molecules and technologies aiming to apply more effective and safer therapy strategies has been intensively explored to overcome this situation. The association of nanoparticles with known antitumor compounds (including plant-derived molecules such as curcumin) has been considered an effective approach to enhance tumor growth suppression and reduce adverse effects. Therefore, the objective of this systematic review was to summarize published data regarding evaluations about efficacy and toxicity of curcumin nanoparticles (Cur-NPs) in in vivo models of breast cancer. The search was carried out in the databases: CINAHL, Cochrane, LILACS, Embase, FSTA, MEDLINE, ProQuest, BSV regional portal, PubMed, ScienceDirect, Scopus, and Web of Science. Studies that evaluated tumor growth in in vivo models of breast cancer and showed outcomes related to Cur-NP treatment (without association with other antitumor molecules) were included. Of the 528 initially gathered studies, 26 met the inclusion criteria. These studies showed that a wide variety of NP platforms have been used to deliver curcumin ( e.g. , micelles, polymeric, lipid-based, metallic). Attachment of poly(ethylene glycol) chains (PEG) and active targeting moieties were also evaluated. Cur-NPs significantly reduced tumor volume/weight, inhibited cancer cell proliferation, and increased tumor apoptosis and necrosis. Decreases in cancer stem cell population and angiogenesis were also reported. All the studies that evaluated toxicity considered Cur-NP treatment to be safe regarding hematological/biochemical markers, damage to major organs, and/or weight loss. These effects were observed in different in vivo models of breast cancer ( e.g. , estrogen receptor-positive, triple-negative, chemically induced) showing better outcomes when compared to treatments with free curcumin or negative controls. This systematic review supports the proposal that Cur-NP is an effective and safe therapeutic approach in in vivo models of breast cancer, reinforcing the currently available evidence that it should be further analyzed in clinical trials for breast cancer treatments.

oncology
Current Understandings and Clinical Translation of Nanomedicines for Breast Cancer Therapy.

Yike Jiang,Ziyi Jiang,Mingzhe Wang,Lan Ma

DOI: https://doi.org/10.1016/j.addr.2021.114034

IF: 16.1

2022-01-01

Advanced Drug Delivery Reviews

Abstract:Breast cancer is one of the most frequently diagnosed cancers that is threatening women's life. Current clinical treatment regimens for breast cancer often involve neoadjuvant and adjuvant systemic therapies, which somewhat are associated with unfavorable features. Also, the heterogeneous nature of breast cancers requires precision medicine that cannot be fulfilled by a single type of systemically administered drug. Taking advantage of the nanocarriers, nanomedicines emerge as promising therapeutic agents for breast cancer that could resolve the defects of drugs and achieve precise drug delivery to almost all sites of primary and metastatic breast tumors (e.g. tumor vasculature, tumor stroma components, breast cancer cells, and some immune cells). Seven nanomedicines as represented by Doxil® have been approved for breast cancer clinical treatment so far. More nanomedicines including both non-targeting and active targeting nanomedicines are being evaluated in the clinical trials. However, we have to realize that the translation of nanomedicines, particularly the active targeting nanomedicines is not as successful as people have expected. This review provides a comprehensive landscape of the nanomedicines for breast cancer treatment, from laboratory investigations to clinical applications. We also highlight the key advances in the understanding of the biological fate and the targeting strategies of breast cancer nanomedicine and the implications to clinical translation.

MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 6: exploration of aromatic substituents.

Targeted Drug Delivery Systems for Curcumin in Breast Cancer Therapy

[Etiology and management of venous pain during intravenous administration of oxaliplatin].

Highly Soluble and Stable, High Release Rate Nanocellulose Codrug Delivery System of Curcumin and AuNPs for Dual Chemo-Photothermal Therapy

Curcumin and its nano-formulations: Defining triple-negative breast cancer targets through network pharmacology, molecular docking, and experimental verification

Nanoscale Formulations: Incorporating Curcumin into Combination Strategies for the Treatment of Lung Cancer

Real-time--directed M-mode echocardiography: a new technique for accurate and rapid quantitation of the fetal preejection period and ventricular ejection time of the right and left ventricles.

Therapeutic Nanoparticles Based on Curcumin and Bamboo Charcoal Nanoparticles for Chemo-Photothermal Synergistic Treatment of Cancer and Radioprotection of Normal Cells

Curcumin Administration Routes in Breast Cancer Treatment

Nanocurcumin in cancer treatment: a comprehensive systematic review

Curcumin, its derivatives, and their nanoformulations: Revolutionizing cancer treatment

Curcumin Delivery Systems: How Far from Clinical Application in Tumor Therapy?

Chapter 14, Materials modelling and characterisation for thermo-mechanics

Enhanced breast cancer therapy using multifunctional lipid-coated nanoparticles combining curcumin chemotherapy and nitric oxide gas delivery

A Novel Folic Acid Receptor-Targeted Drug Delivery System Based on Curcumin-Loaded β-Cyclodextrin Nanoparticles for Cancer Treatment

Nano to rescue: repository of nanocarriers for targeted drug delivery to curb breast cancer

[Immunomapping in localized bullous pemphigoid].

Platinum nanoparticles-embedded single-walled carbon nanotubes as a new carrier for curcumin delivery and investigating its anticancer effect on cell line 4T1

Development of curcumin-loaded galactosylated chitosan-coated nanoparticles for targeted delivery of hepatocellular carcinoma

In Vivo Efficacy and Toxicity of Curcumin Nanoparticles in Breast Cancer Treatment: A Systematic Review

Current Understandings and Clinical Translation of Nanomedicines for Breast Cancer Therapy.